Fig. 3. Gilteritinib reduces FLT3 expression in other AML cell lines. Western blot analysis of FLT3 expression in (A) MOLM-13, (B) EOL-1, and (C) HL-60 cells treated with different concentrations of gilteritinib for 24 h. β-Actin was used as a loading control.
© Biomolecules & Therapeutics
